Clinical profile, prevalence and mortality of hospitalized patients with chronic liver diseases infected with SARS-COV-2: An integrative review




Chronic liver disease; Coronavirus infection; Coinfection; Mortality.


Objective: To analyze scientific evidence on the clinical profile, prevalence and mortality of adult hospitalized patients with chronic liver disease (CLD) infected with SARS-COV-2. Methodology: This is a bibliographic review in the integrative literature review method, carried out in February 2021, in the databases MEDLINE / PubMed, EMBASE and LILACS, using the descriptors / MESH: "COVID-19" AND "chronic liver disease ", combined with the Boolean operator "AND”. Inclusion criteria were: original articles available in full, complete, published between 2019 and January 2021, in Portuguese, English and/or Spanish, and a suitable theme. The exclusion criteria were: incomplete, duplicate articles, unrelated to the topic, in pre-proof, theses, dissertations, monographs and manuals. Results: Seven articles were included. 1693 adult hospitalized patients infected with SARS-COV-2 were analyzed and the frequency was varied between 0.79% and 50%, compared to the hospitalized population infected with COVID-19 with and without CLD. The clinical profile of patients with CLD and COVID-19 was predominantly male, mean age: 55 years, non-alcoholic fatty liver disease as a previous CLD and hypertension as the main comorbidity. The most reported symptoms were cough (80.8%), presence of infection(73.1%), sputum(26.9%), dyspnea(25%), myalgia or fatigue(13.5%). The main laboratory and imaging changes included elevation in liver enzymes, lymphopenia, diffuse opacities and ground-glass. Mortality was more significant in immunosuppressed CLD and COVID-19 patients, ranging from 1.78% to 8.1%. Conclusion: The data propose a trend in clinical profile, prevalence and mortality, but there is a need for further cohort studies or randomized clinical trials with larger samples to confirm hypotheses.


Barry, A., Apisarnthanarax, S., O'Kane, G. M., Sapisochin, G., Beecroft, R., Salem, R., ... & Hawkins, M. A. (2020). Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. The Lancet Gastroenterology & Hepatology.

Gautret, P., Million, M., Jarrot, P. A., Camoin-Jau, L., Colson, P., Fenollar, F., ... & Raoult, D. (2020). Natural history of COVID-19 and therapeutic options. Expert Review of Clinical Immunology, 1-24.

Gómez, J. L., Aldana, A. J. G., & Mantilla, M. L. T. (2020). Implicaciones hepáticas en la pandemia por COVID-19. Revista Colombiana de Gastroenterología, 35(Supl. 1), 30-36.

Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., ... & Pesenti, A. (2020). Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. Jama, 323(16), 1574-1581.

Ji, D., Zhang, D., Yang, T., Mu, J., Zhao, P., Xu, J., ... & Lau, G. (2020). Effect of COVID-19 on patients with compensated chronic liver diseases. Hepatology international, 14(5), 701-710.

Jothimani, D., Venugopal, R., Abedin, M. F., Kaliamoorthy, I., & Rela, M. (2020). COVID-19 and Liver. Journal of hepatology.

Koche, J. C. (2011). Fundamentos de metodologia científica: teoria da ciência e iniciação à pesquisa. 1 ed. Petrópolis, RJ: Vozes.

Kovalic, A. J., Satapathy, S. K., & Thuluvath, P. J. (2020). Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. Hepatology international, 1-9.

Li, C., Chen, Q., Wang, J., Lin, H., Lin, Y., Lin, J., ... & Yang, Z. (2020). Clinical characteristics of chronic liver disease with coronavirus disease 2019 (COVID-19): a cohort study in Wuhan, China. Aging (Albany NY), 12(16), 15938.

Mantovani, A., Beatrice, G., & Dalbeni, A. (2020). Coronavirus disease 2019 and prevalence of chronic liver disease: A meta‐analysis. Liver International, 40(6), 1316-1320.

Moon, A. M., Singal, A. G., & Tapper, E. B. (2019). Contemporary epidemiology of chronic liver disease and cirrhosis. Clinical Gastroenterology and Hepatology.

Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018).Metodologia da pesquisa científica.[e-book]. Santa Maria. Ed (pp. 3-9). UAB/NTE/UFSM. https://repositorio. ufsm. br/bitstream/handle/1/15824/Lic_Computacao_Metodologia-Pesquisa - Cientifica. pdf.

Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., ... & Zanos, T. P. (2020). Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. Jama, 323(20), 2052-2059.

Stasi, C., Fallani, S., Voller, F., & Silvestri, C. (2020). Treatment for COVID-19: An overview. European Journal of Pharmacology, 173644.

Teich, V. D., Klajner, S., Almeida, F. A. S. D., Dantas, A. C. B., Laselva, C. R., Torritesi, M. G., ... & Cendoroglo Neto, M. (2020). Características epidemiológicas e clínicas dos pacientes com COVID-19 no Brasil. Einstein (São Paulo), 18.

Wang, Q., Davis, P. B., & Xu, R. (2020). COVID-19 risk, disparities and outcomes in patients with chronic liver disease in the United States. EClinicalMedicine, 100688.

Xiao, Y., Pan, H., She, Q., Wang, F., & Chen, M. (2020). Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis. The Lancet Gastroenterology & Hepatology, 5(6), 528-529.

Zhan, K. et al., (2021). Risk factors in patients with COVID-19 developing severe liver injury during hospitalisation. Gut, 70(3), 628-629.



How to Cite

AFONSO, T. de O.; FREITAS, S. M. S. de; SOUZA, D. R. F. de; ANDRADE, G. V. L. de; GONÇALVES, J. E.; SILVA, M. P. B.; SANTOS, S. L. dos; CARVALHO, S. B. de .; LOURES, L. L. da S. .; ARAUJO, G. B. .; MELO, B. C.; GOMES, Y. M.; BRAYNER, L. E. A. N. .; FONSECA, N. M. N. da .; CARVALHO, M. C. O. M.; ZANOVELLO, M. M. B. .; MIRANDA, I. M. M. B. .; SANTOS, A. V.; MACIEL, A. C.; RIBEIRO, Y. C. .; BRITO, P. F. Clinical profile, prevalence and mortality of hospitalized patients with chronic liver diseases infected with SARS-COV-2: An integrative review. Research, Society and Development, [S. l.], v. 10, n. 4, p. e33010413143, 2021. DOI: 10.33448/rsd-v10i4.13143. Disponível em: Acesso em: 19 jun. 2021.



Health Sciences